Diagnostic stewardship for blood cultures in the emergency department: A multicenter validation and prospective evaluation of a machine learning prediction tool.

Blood cultures Decision-curve analysis Emergency department Machine learning Validation

Journal

EBioMedicine
ISSN: 2352-3964
Titre abrégé: EBioMedicine
Pays: Netherlands
ID NLM: 101647039

Informations de publication

Date de publication:
Aug 2022
Historique:
received: 06 05 2022
revised: 16 06 2022
accepted: 04 07 2022
pubmed: 20 7 2022
medline: 17 8 2022
entrez: 19 7 2022
Statut: ppublish

Résumé

Overuse of blood cultures (BCs) in emergency departments (EDs) leads to low yields and high numbers of contaminated cultures, accompanied by increased diagnostics, antibiotic usage, prolonged hospitalization, and mortality. We aimed to simplify and validate a recently developed machine learning model to help safely withhold BC testing in low-risk patients. We extracted data from the electronic health records (EHR) for 44.123 unique ED visits with BC sampling in the Amsterdam UMC (locations VUMC and AMC; the Netherlands), Zaans Medical Center (ZMC; the Netherlands), and Beth Israel Deaconess Medical Center (BIDMC; United States) in periods between 2011 and 2021. We trained a machine learning model on the VUMC data to predict blood culture outcomes and validated it in the AMC, ZMC, and BIDMC with subsequent real-time prospective evaluation in the VUMC. The model had an Area Under the Receiver Operating Characteristics curve (AUROC) of 0.81 (95%-CI = 0.78-0.83) in the VUMC test set. The most important predictors were temperature, creatinine, and C-reactive protein. The AUROCs in the validation cohorts were 0.80 (AMC; 0.78-0.82), 0.76 (ZMC; 0.74-0.78), and 0.75 (BIDMC; 0.74-0.76). During real-time prospective evaluation in the EHR of the VUMC, it reached an AUROC of 0.76 (0.71-0.81) among 590 patients with BC draws in the ED. The prospective evaluation showed that the model can be used to safely withhold blood culture analyses in at least 30% of patients in the ED. We developed a machine learning model to predict blood culture outcomes in the ED, which retained its performance during external validation and real-time prospective evaluation. Our model can identify patients at low risk of having a positive blood culture. Using the model in practice can significantly reduce the number of blood culture analyses and thus avoid the hidden costs of false-positive culture results. This research project was funded by the Amsterdam Public Health - Quality of Care program and the Dutch "Doen of Laten" project (project number: 839205002).

Sections du résumé

BACKGROUND BACKGROUND
Overuse of blood cultures (BCs) in emergency departments (EDs) leads to low yields and high numbers of contaminated cultures, accompanied by increased diagnostics, antibiotic usage, prolonged hospitalization, and mortality. We aimed to simplify and validate a recently developed machine learning model to help safely withhold BC testing in low-risk patients.
METHODS METHODS
We extracted data from the electronic health records (EHR) for 44.123 unique ED visits with BC sampling in the Amsterdam UMC (locations VUMC and AMC; the Netherlands), Zaans Medical Center (ZMC; the Netherlands), and Beth Israel Deaconess Medical Center (BIDMC; United States) in periods between 2011 and 2021. We trained a machine learning model on the VUMC data to predict blood culture outcomes and validated it in the AMC, ZMC, and BIDMC with subsequent real-time prospective evaluation in the VUMC.
FINDINGS RESULTS
The model had an Area Under the Receiver Operating Characteristics curve (AUROC) of 0.81 (95%-CI = 0.78-0.83) in the VUMC test set. The most important predictors were temperature, creatinine, and C-reactive protein. The AUROCs in the validation cohorts were 0.80 (AMC; 0.78-0.82), 0.76 (ZMC; 0.74-0.78), and 0.75 (BIDMC; 0.74-0.76). During real-time prospective evaluation in the EHR of the VUMC, it reached an AUROC of 0.76 (0.71-0.81) among 590 patients with BC draws in the ED. The prospective evaluation showed that the model can be used to safely withhold blood culture analyses in at least 30% of patients in the ED.
INTERPRETATION CONCLUSIONS
We developed a machine learning model to predict blood culture outcomes in the ED, which retained its performance during external validation and real-time prospective evaluation. Our model can identify patients at low risk of having a positive blood culture. Using the model in practice can significantly reduce the number of blood culture analyses and thus avoid the hidden costs of false-positive culture results.
FUNDING BACKGROUND
This research project was funded by the Amsterdam Public Health - Quality of Care program and the Dutch "Doen of Laten" project (project number: 839205002).

Identifiants

pubmed: 35853298
pii: S2352-3964(22)00357-7
doi: 10.1016/j.ebiom.2022.104176
pmc: PMC9294655
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

104176

Informations de copyright

Copyright © 2022 The Author(s). Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests The authors declare no competing interests pertaining to the submitted work.

Auteurs

Michiel Schinkel (M)

Section General Internal Medicine, Department of Internal Medicine, Amsterdam Public Health Research Institute, Amsterdam UMC, location VU University Medical Center, De Boelelaan 1118, 1081 HZ Amsterdam, the Netherlands; Center for Experimental and Molecular Medicine (CEMM), Amsterdam UMC, location Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands.

Anneroos W Boerman (AW)

Section General Internal Medicine, Department of Internal Medicine, Amsterdam Public Health Research Institute, Amsterdam UMC, location VU University Medical Center, De Boelelaan 1118, 1081 HZ Amsterdam, the Netherlands; Department of Clinical Chemistry, Amsterdam UMC, Vrije Universiteit Amsterdam, AGEM Research Institute, De Boelelaan 1118, 1081 HZ Amsterdam, the Netherlands.

Frank C Bennis (FC)

Department of Computer Science, Quantitative Data Analytics Group, Department of Computer Science, Faculty of Science, VU University, De Boelelaan 1105, 1081HV Amsterdam, the Netherlands.

Tanca C Minderhoud (TC)

Section General Internal Medicine, Department of Internal Medicine, Amsterdam Public Health Research Institute, Amsterdam UMC, location VU University Medical Center, De Boelelaan 1118, 1081 HZ Amsterdam, the Netherlands.

Mei Lie (M)

Department of EVA Service Center, Amsterdam UMC, location VU University Medical Center, De Boelelaan 1118, 1081 HZ Amsterdam, the Netherlands; Department of EVA Service Center, Amsterdam UMC, location Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands.

Hessel Peters-Sengers (H)

Center for Experimental and Molecular Medicine (CEMM), Amsterdam UMC, location Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands.

Frits Holleman (F)

Section General and Acute Internal Medicine, Department of Internal Medicine, Amsterdam UMC, location Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands.

Rogier P Schade (RP)

Department of Medical Microbiology and Infection Prevention, Amsterdam UMC, location Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands.

Robert de Jonge (R)

Department of Clinical Chemistry, Amsterdam UMC, Vrije Universiteit Amsterdam, AGEM Research Institute, De Boelelaan 1118, 1081 HZ Amsterdam, the Netherlands.

W Joost Wiersinga (WJ)

Center for Experimental and Molecular Medicine (CEMM), Amsterdam UMC, location Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands; Section Infectious Diseases, Department of Internal Medicine, Amsterdam UMC, location Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands.

Prabath W B Nanayakkara (PWB)

Section General Internal Medicine, Department of Internal Medicine, Amsterdam Public Health Research Institute, Amsterdam UMC, location VU University Medical Center, De Boelelaan 1118, 1081 HZ Amsterdam, the Netherlands. Electronic address: p.nanayakkara@amsterdamumc.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH